Program in Antimicrobial Resistance and Drug Discovery
The Program in Antimicrobial Resistance and Drug Discovery is focused on tackling the third leading cause of death due to infectious disease worldwide - antibiotic resistant bacteria.
- Advance understanding on how existing antimicrobials act and define the mechanisms of bacterial drug resistance and drug tolerance through basic experimental research.
- Partner with clinicians and public health labs to expand the ability to monitor and identify emerging antibiotic resistance threats
Recent Development: New Assays to Help Streamline Drug Discovery
New work from the lab of Courtney Aldrich, PhD in theDepartment of Medicinal Chemistry and his collaborators focuses on expediting the drug discovery process to treat important infectious diseases such as Tuberculosis.
They developed cell-based assays that utilize two-way regulation of protein expression to readily identify on-target inhibitors of essential genes in Mycobacterium tuberculosis. These assays can be used to supplement the traditional whole-cell screening process, which remains a powerful but often complicated and time-consuming process in screening potential drugs to inhibit the activity of Biotin Protein Ligase; BirA.
Image credit: Federation of American Societies of Experimental Biology. DOI: https://doi.org/10.1096/fasebj.2022.36.S1.L7723